SageView Advisory Group LLC acquired a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 3,806 shares of the company’s stock, valued at approximately $285,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners lifted its holdings in Henry Schein by 144.1% during the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after purchasing an additional 1,556,831 shares during the last quarter. Norges Bank bought a new position in shares of Henry Schein in the fourth quarter valued at approximately $111,715,000. Nuance Investments LLC acquired a new position in shares of Henry Schein in the 4th quarter worth approximately $103,446,000. Lazard Asset Management LLC grew its position in Henry Schein by 1,303.3% during the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after acquiring an additional 1,158,451 shares during the last quarter. Finally, Fiduciary Management Inc. WI increased its holdings in Henry Schein by 17.1% during the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock valued at $172,947,000 after purchasing an additional 333,855 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.
Henry Schein Price Performance
HSIC opened at $66.55 on Friday. The company has a fifty day moving average price of $70.52 and a two-hundred day moving average price of $73.11. The firm has a market capitalization of $8.52 billion, a PE ratio of 22.48, a P/E/G ratio of 1.68 and a beta of 0.90. Henry Schein, Inc. has a 52 week low of $60.01 and a 52 week high of $82.63. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75.
Wall Street Analyst Weigh In
A number of equities analysts have commented on HSIC shares. Evercore ISI boosted their price objective on Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research note on Wednesday, February 28th. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Jefferies Financial Group upped their target price on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. Finally, Barrington Research raised their price target on shares of Henry Schein from $90.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $81.73.
Check Out Our Latest Research Report on Henry Schein
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Stories
- Five stocks we like better than Henry Schein
- How Technical Indicators Can Help You Find Oversold Stocks
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- What is the Australian Securities Exchange (ASX)
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- What is a Dividend King?
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.